Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neuronetics Inc
(NQ:
STIM
)
0.7400
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neuronetics Inc
< Previous
1
2
Next >
Neuronetics Wins 2023 Bell Seal for Workplace Mental Health
May 15, 2023
The Company is recognized for its commitment to employees’ well-being
From
Neuronetics
Via
GlobeNewswire
Neuronetics Receives MDSAP Certification and CE Mark Certification under New MDR
May 08, 2023
Achievement demonstrates Company’s commitment to rigorous standards for safe and effective products
From
Neuronetics
Via
GlobeNewswire
Neuronetics Showcases New NeuroStar® TMS Findings at Clinical TMS Society Annual Meeting
May 03, 2023
Data highlights the Company’s commitment to advancing TMS and improving patient outcomes
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Expands “Tap Into Possibility” Campaign in Honor of Mental Health Awareness Month
May 02, 2023
Campaign features patients’ experiences to support others with depression
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer
May 01, 2023
Strategic role strengthens NeuroStar® Advanced Therapy commercialization team
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Expanded TMS Access through United HealthCare
April 28, 2023
UHC Medicare Advantage plans in NGS states expand access via NPPs
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Continued Momentum for Expanded Health Insurance Coverage for TMS Therapy
April 13, 2023
BlueCross BlueShield of Mississippi Latest to Allow Non-Physician Practitioners to Prescribe TMS
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities
April 06, 2023
Fifth FDA clearance in less than two years offers greater connectivity and flexibility to improve the patient and provider experience
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
March 16, 2023
Award recognizes NeuroStar for its significant contributions toward patient wellbeing
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces TMS Coverage Criteria Changes for Over 23 Million Covered Lives
March 02, 2023
United HealthCare Optum Reduces Barriers to TMS Eligibility for Depression Patients
From
Neuronetics
Via
GlobeNewswire
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
February 23, 2023
Company Launches a New Educational Campaign For Providers
From
Neuronetics
Via
GlobeNewswire
Neuronetics Sponsors the 5th International Brain Stimulation Conference
February 21, 2023
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
February 16, 2023
New Senior Leadership Role Will Streamline Alignment of All Company Revenue-Generating Functions
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
February 10, 2023
NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
January 17, 2023
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
December 05, 2022
NeuroStar’s technology once again recognized as an effective non-drug treatment for patients
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
November 14, 2022
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
October 31, 2022
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
October 25, 2022
Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS
From
Neuronetics
Via
GlobeNewswire
Artificial Intelligence Could Be About To Replace Your Doctor
November 02, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector
October 18, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The Law Offices of Frank R. Cruz Announces Investigation of Neuronetics, Inc. (STIM) on Behalf of Investors
October 14, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Betting Big On What Could Be The Next Great Biotech Boom
May 18, 2021
Via
FinancialNewsMedia
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.